Dasatinib excels in worldwide phase II trial against pediatric CML
In 2002, the FDA approved the drug imatinib as a first-line therapy for adults with chronic myeloid leukemia (CML) caused by the fusion gene BCR-ABL, known as the Philadelphia chromosome. The approval dramatically extended ...
Jun 5, 2017
0
1